Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs.
Hooft van Huijsduijnen
Rob
R
Serono Pharmaceutical Research Institute, Chemin des Aulx 14, 1228 Plan-les-Ouates, Geneva, Switzerland. rob.hooft@serono.com
Sauer
Wolfgang H B
WH
Bombrun
Agnes
A
Swinnen
Dominique
D
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000201:enzymology; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D009765:Obesity / Q000201:enzymology; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors*
D007004:Hypoglycemic Agents; C516607:PTPN1 protein, human; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases; D005947:Glucose